Dr. Firestein has studied the role of aggressive synoviocyte behavior in RA as a mechanism of joint destruction and implicated tumor suppressor genes mutations in the pathogenesis of disease. Over the last decade, his laboratory has worked extensively on signal transduction pathways as potential therapeutic targets. These studies identified key signaling molecules regulating synovial inflammation and paved the way to several effective oral small molecule inhibitors that are currently in late phase clinical development for RA. More recently, Dr. Firestein has focused on epigenetics and discovered a DNA methylation signature specific to RA. In addition, he directed a number of innovative clinical studies for the treatment of rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, scleroderma, and autoinflammatory syndromes with a focus on developing novel biomarker endpoints. His group developed novel biomarker studies using serial synovial biopsy studies in RA to understand the mechanism of action for anti-rheumatic agents.
Support our work
Your gifts help us bridge the gap between discovery and patient care. To partner directly with us please contact: firstname.lastname@example.org